Biomarker & Intervention Discovery

Chronic Lymphocytic Leukaemia (CLL)

This page lists 11 druggable gene targets, 47 approved or trial-tested drug candidates and 15 recent clinical trials for Chronic Lymphocytic Leukaemia (CLL), with each agent ranked by the strength of its evidence (clinical, mechanistic or correlative). Candidates include existing drugs that could be repurposed. Sources are linked so you can check every claim.

Spontaneous remissionEarly-stage (Rai 0-I): watch-and-wait appropriate in 50-70%; spontaneous remission extremely rare; median time to…
Best-intervention remissionVenetoclax + obinutuzumab (CLL14): 2-year fixed duration, MRD-undetectable remission in 36%, PFS benefit sustained at…
Gap sizeLarge — chlorambucil still used in some elderly patients; BTK inhibitor choice and venetoclax combination timing are…
Primary barrierpractice/access
Full remission profile →
Research Tracker Chronic Disease Interventions Chronic Lymphocytic Leukaemia (CLL)

Remission & chronicity

Spontaneous remission
Early-stage (Rai 0-I): watch-and-wait appropriate in 50-70%; spontaneous remission extremely rare; median time to treatment in Rai Stage 0: 10+ years; Richter's transformation (5-10%) extremely poor prognosis
Best-intervention remission
Venetoclax + obinutuzumab (CLL14): 2-year fixed duration, MRD-undetectable remission in 36%, PFS benefit sustained at 5 years vs chlorambucil; ibrutinib continuous: PFS benefit but not curative; BRUIN CLL trial (pirtobrutinib): 73% ORR in ibrutinib-resistant CLL
Gap size
Large — chlorambucil still used in some elderly patients; BTK inhibitor choice and venetoclax combination timing are practice-variable
Primary barrier
practice/access
Chemoimmunotherapy (FCR, BR) largely replaced by BTK inhibitors and venetoclax but chlorambucil still used where cost is a barrier; the 'best drug at first relapse' question is evolving rapidly; CAR-T not yet standard for CLL

Biomarker Targets & Therapeutic Agents

Gene targets queried against DGIdb, Open Targets, ChEMBL, PubMed, and Europe PMC. Agents ranked: Clinical > Mechanistic > Correlative.

ATM 281BCL2 214BTK 254CD19 40CD38 203CD52 4MS4A1 28NOTCH1 122PIK3CD 302TP53 652ZAP70 192

ATM

UniProt Ensembl DGIdb Open Targets
Therapeutic Agent Effect Direction Evidence Tier Potency Source
ETOPOSIDE ? unclear Mechanistic DGIdb
CP466722 ↓ inhibits Mechanistic DGIdb
VELIPARIB ? unclear Mechanistic DGIdb
CISPLATIN ? unclear Mechanistic DGIdb
OLAPARIB ? unclear Mechanistic DGIdb
EVEROLIMUS ? unclear Mechanistic DGIdb
DOXORUBICIN HYDROCHLORIDE ? unclear Mechanistic DGIdb
TEMOZOLOMIDE ? unclear Mechanistic DGIdb
NIRAPARIB ? unclear Mechanistic DGIdb
AZD1390 ↓ inhibits Mechanistic DGIdb
SCHISANHENOL ? unclear Mechanistic DGIdb
INDISULAM ? unclear Mechanistic DGIdb
PARP/TANKYRASE INHIBITOR 2X-121 ? unclear Mechanistic DGIdb
XRD-0394 ↓ inhibits Mechanistic DGIdb
DIPYRIDAMOLE ? unclear Mechanistic DGIdb
ALNODESERTIB ? unclear Mechanistic DGIdb
PHLORETIN ? unclear Mechanistic DGIdb
DURVALUMAB ? unclear Mechanistic DGIdb
IBRUTINIB ? unclear Mechanistic DGIdb
LARTESERTIB ↓ inhibits Mechanistic DGIdb
CERALASERTIB ? unclear Mechanistic DGIdb
ENPIROLINE ? unclear Mechanistic DGIdb
ENZALUTAMIDE ? unclear Mechanistic DGIdb
VALPROIC ACID ? unclear Mechanistic DGIdb
IRINOTECAN HYDROCHLORIDE ? unclear Mechanistic DGIdb
FLUOROURACIL ? unclear Mechanistic DGIdb
A011 ↓ inhibits Mechanistic DGIdb
VANDETANIB ? unclear Mechanistic DGIdb
DITHIAZANINE IODIDE ? unclear Mechanistic DGIdb
CHEMBL:CHEMBL374632 ? unclear Mechanistic DGIdb
BENDAMUSTINE ? unclear Mechanistic DGIdb
AZD0156 ↓ inhibits Mechanistic DGIdb
PJ34 ? unclear Mechanistic DGIdb
KU-0060648 ? unclear Mechanistic DGIdb
CYCLOPHOSPHAMIDE ANHYDROUS ? unclear Mechanistic DGIdb
TOLONIUM CHLORIDE ? unclear Mechanistic DGIdb
PEGYLATED SN-38 CONJUGATE PLX038 ? unclear Mechanistic DGIdb
IPILIMUMAB ? unclear Mechanistic DGIdb
AVELUMAB ? unclear Mechanistic DGIdb
OXALIPLATIN ? unclear Mechanistic DGIdb

Showing top 40 of 281 agents ranked by evidence tier.

BCL2

UniProt Ensembl DGIdb Open Targets
Therapeutic Agent Effect Direction Evidence Tier Potency Source
NONSTEROIDAL ANTIINFLAMMATORY DRUG ? unclear Mechanistic DGIdb
ENDOTHELIN RECEPTOR ANTAGONIST ? unclear Mechanistic DGIdb
BORTEZOMIB ? unclear Mechanistic DGIdb
DOXORUBICIN HYDROCHLORIDE ? unclear Mechanistic DGIdb
MITOXANTRONE HYDROCHLORIDE ? unclear Mechanistic DGIdb
VENETOCLAX ↓ inhibits Mechanistic DGIdb
NAVITOCLAX ↓ inhibits Mechanistic DGIdb
ISOTRETINOIN ? unclear Mechanistic DGIdb
BRENTUXIMAB VEDOTIN ? unclear Mechanistic DGIdb
OXALIPLATIN ? unclear Mechanistic DGIdb
TAZAROTENE ? unclear Mechanistic DGIdb
LISAFTOCLAX ↓ inhibits Mechanistic DGIdb
GOSSYPOL ? unclear Mechanistic 320.0 nM (Ki) DGIdb
EDARAVONE ? unclear Mechanistic DGIdb
TENIPOSIDE ? unclear Mechanistic DGIdb
DITIOCARB ? unclear Mechanistic DGIdb
CARBOPLATIN ? unclear Mechanistic DGIdb
CILENGITIDE ? unclear Mechanistic DGIdb
ESTRAMUSTINE ? unclear Mechanistic DGIdb
RECOMBINANT INTERFERON ? unclear Mechanistic DGIdb
CISPLATIN ? unclear Mechanistic DGIdb
AZD4320 ↓ inhibits Mechanistic DGIdb
PELCITOCLAX ? unclear Mechanistic DGIdb
ORAL CONTRACEPTIVE ? unclear Mechanistic DGIdb
ANG1005 ? unclear Mechanistic DGIdb
OBATOCLAX ↓ inhibits Mechanistic DGIdb
ANTI-CD19 CAR T CELLS AT101 ↓ inhibits Mechanistic DGIdb
FOSBRETABULIN DISODIUM ? unclear Mechanistic DGIdb
APG-1252-M1 ↓ inhibits Mechanistic DGIdb
SONROTOCLAX ↓ inhibits Mechanistic DGIdb
DULANERMIN ? unclear Mechanistic DGIdb
RALTITREXED ? unclear Mechanistic DGIdb
EPIRUBICIN HYDROCHLORIDE ? unclear Mechanistic DGIdb
ETOPOSIDE ? unclear Mechanistic DGIdb
MULTIDRUG RESISTANCE MODULATOR ? unclear Mechanistic DGIdb
BCL-2 INHIBITOR BCL201 ? unclear Mechanistic DGIdb
PROTUBOXEPIN A ? unclear Mechanistic DGIdb
RIBAVIRIN ? unclear Mechanistic DGIdb
DIETHYLSTILBESTROL ? unclear Mechanistic DGIdb
APRINOCARSEN ? unclear Mechanistic DGIdb

Showing top 40 of 214 agents ranked by evidence tier.

BTK

UniProt Ensembl DGIdb Open Targets
Therapeutic Agent Effect Direction Evidence Tier Potency Source
PRN694 ↓ inhibits Mechanistic DGIdb
RN486 ↓ inhibits Mechanistic DGIdb
PD166285 ? unclear Mechanistic DGIdb
PTD10 ↓ inhibits Mechanistic DGIdb
BRANEBRUTINIB ↓ inhibits Mechanistic DGIdb
ACALABRUTINIB ↓ inhibits Mechanistic DGIdb
COMPOUND 71 [WO2018191577A1] ↓ inhibits Mechanistic DGIdb
COMPOUND 25 [PMID: 31260299] ↓ inhibits Mechanistic DGIdb
COMPOUND 38 [PMID: 24915291] ↓ inhibits Mechanistic DGIdb
IBRUTINIB ↓ inhibits Mechanistic 0.5 nM (IC50) DGIdb
ZM447439 ? unclear Mechanistic DGIdb
BTK INHIBITOR TL-895 ? unclear Mechanistic DGIdb
ZYBT1 ↓ inhibits Mechanistic DGIdb
EVOBRUTINIB ↓ inhibits Mechanistic DGIdb
FENEBRUTINIB ↓ inhibits Mechanistic DGIdb
TOLEBRUTINIB ↓ inhibits Mechanistic DGIdb
RILZABRUTINIB ? unclear Mechanistic DGIdb
CGI1746 ↓ inhibits Mechanistic DGIdb
TAMATINIB ? unclear Mechanistic DGIdb
ZANUBRUTINIB ↓ inhibits Mechanistic DGIdb
ENTRECTINIB ? unclear Mechanistic 158.49 nM (Ki) DGIdb
LUXEPTINIB ↓ inhibits Mechanistic DGIdb
BTK INHIBITOR 16 [PMID: 30122225] ↓ inhibits Mechanistic DGIdb
ZELEBRUDOMIDE ? unclear Mechanistic DGIdb
BIIB068 ↓ inhibits Mechanistic DGIdb
PROTAC 23 [PMID: 38321747] ↓ inhibits Mechanistic DGIdb
NVP-TAE684 ? unclear Mechanistic DGIdb
COMPOUND 36 [PMID: 21958547] ↓ inhibits Mechanistic DGIdb
CINSEBRUTINIB ↓ inhibits Mechanistic DGIdb
COMPOUND 9 [PMID: 26006010] ↓ inhibits Mechanistic DGIdb
DASATINIB ANHYDROUS ? unclear Mechanistic DGIdb
NEMTABRUTINIB ? unclear Mechanistic DGIdb
JNJ-64264681 ↓ inhibits Mechanistic DGIdb
SPEBRUTINIB ↓ inhibits Mechanistic DGIdb
CHEMBL:CHEMBL1997335 ? unclear Mechanistic DGIdb
RITLECITINIB ↓ inhibits Mechanistic DGIdb
BIRELENTINIB ↓ inhibits Mechanistic DGIdb
PF-562271 ? unclear Mechanistic DGIdb
ORELABRUTINIB ↓ inhibits Mechanistic DGIdb
MIDOBRUTINIB ↓ inhibits Mechanistic DGIdb

Showing top 40 of 254 agents ranked by evidence tier.

CD19

UniProt Ensembl DGIdb Open Targets
Therapeutic Agent Effect Direction Evidence Tier Potency Source
AUTOLOGOUS ANTI-CD19 CAR T-CELLS IM19 ? unclear Mechanistic DGIdb
BLINATUMOMAB ? unclear Mechanistic DGIdb
LONCASTUXIMAB TESIRINE ~ modulates Mechanistic DGIdb
AUTOLOGOUS CD19CAR-CD28-CD137/CD27/CD3ZETA-ICASP9-EXPRESSING T-LYMPHOCYTES ? unclear Mechanistic DGIdb
TISAGENLECLEUCEL ? unclear Mechanistic DGIdb
AUTOLOGOUS ANTI-CD19 CHIMERIC ANTIGEN RECEPTOR T-CELLS C-CAR011 ? unclear Mechanistic DGIdb
VADACABTAGENE LERALEUCEL ? unclear Mechanistic DGIdb
LISOCABTAGENE MARALEUCEL ? unclear Mechanistic DGIdb
AUTOLOGOUS ANTI-CD19CAR-4-1BB-CD3ZETA-EGFRT-EXPRESSING T LYMPHOCYTES ? unclear Mechanistic DGIdb
MDX-1342 ~ modulates Mechanistic DGIdb
AXICABTAGENE CILOLEUCEL ? unclear Mechanistic DGIdb
ANTI-CD19 CAR T CELLS PREPARATION ? unclear Mechanistic DGIdb
INEBILIZUMAB ? unclear Mechanistic DGIdb
ALLOGENEIC ANTI-CD19-CAR-CD28-IL-15-EXPRESSING NATURAL KILLER T-CELLS ? unclear Mechanistic DGIdb
AZERCABTAGENE ZAPRELEUCEL ? unclear Mechanistic DGIdb
TAFASITAMAB ? unclear Mechanistic DGIdb
DENINTUZUMAB MAFODOTIN ~ modulates Mechanistic DGIdb
COLTUXIMAB RAVTANSINE ? unclear Mechanistic DGIdb
OBEXELIMAB ↓ inhibits Mechanistic DGIdb
AMG-729 ~ modulates Mechanistic DGIdb
CD19CAR-CD3ZETA-4-1BB-EXPRESSING ALLOGENEIC T-LYMPHOCYTE CELLS ? unclear Mechanistic DGIdb
AUTOLOGOUS ANTI-CD19 CAR-T CELLS TBI-1501 ? unclear Mechanistic DGIdb
AUTOLOGOUS CD19 CAR-EXPRESSING CD4+/CD8+ T-CELLS MB-CART19.1 ? unclear Mechanistic DGIdb
AFM-11 ? unclear Mechanistic DGIdb
BREXUCABTAGENE AUTOLEUCEL ~ modulates Mechanistic DGIdb
TAPLITUMOMAB PAPTOX ~ modulates Mechanistic DGIdb
ANTI-CD19 CAR T-CELLS XLCART001 ? unclear Mechanistic DGIdb
AUTOLOGOUS ANTI-CD19 CAR-EXPRESSING T-LYMPHOCYTES CLIC-1901 ? unclear Mechanistic DGIdb
DENINTUZUMAB ~ modulates Mechanistic DGIdb
AUTO3 ? unclear Mechanistic DGIdb
DEGLYCOSYLATED RICIN A CHAIN-CONJUGATED ANTI-CD19/ANTI-CD22 IMMUNOTOXINS ? unclear Mechanistic DGIdb
DUVORTUXIZUMAB ? unclear Mechanistic DGIdb
ANTI-CD19 CAR-T CELLS ? unclear Mechanistic DGIdb
AUTOLOGOUS ANTI-CD19 CHIMERIC ANTIGEN RECEPTOR T-CELLS SJCAR19 ? unclear Mechanistic DGIdb
ONCOLYSIN B ~ modulates Mechanistic DGIdb
ANTI-CD20 CAR T CELLS PREPARATION ? unclear Mechanistic DGIdb
CD19-TARGETED CAR T2 CELLS ? unclear Mechanistic DGIdb
OBECABTAGENE AUTOLEUCEL ~ modulates Mechanistic DGIdb
JCAR014 ? unclear Mechanistic DGIdb
RELMACABTAGENE AUTOLEUCEL ? unclear Mechanistic DGIdb

CD38

UniProt Ensembl DGIdb Open Targets
Therapeutic Agent Effect Direction Evidence Tier Potency Source
ANTI-CD38 CAR T CELLS PREPARATION ? unclear Mechanistic DGIdb
MEZAGITAMAB ~ modulates Mechanistic DGIdb
THROMBIN ALFA ? unclear Mechanistic DGIdb
ISATUXIMAB ? unclear Mechanistic DGIdb
DARATUMUMAB ↓ inhibits Mechanistic DGIdb
HUMAX-IL15 ↓ inhibits Mechanistic DGIdb
MK-0159 ↓ inhibits Mechanistic DGIdb
FELZARTAMAB ↓ inhibits Mechanistic DGIdb
KUROMANIN ↓ inhibits Mechanistic 6300.0 nM (IC50) ChEMBL
DELPHINIDIN ↓ inhibits Mechanistic 14600.0 nM (IC50) ChEMBL
PELARGONIDIN ↓ inhibits Mechanistic 16300.0 nM (IC50) ChEMBL
MALVIDIN ↓ inhibits Mechanistic 17000.0 nM (IC50) ChEMBL
QUERCETAGETINIDIN ↓ inhibits Mechanistic 14200.0 nM (IC50) ChEMBL
PEONIDIN ↓ inhibits Mechanistic 20900.0 nM (IC50) ChEMBL
CYANIDIN ↓ inhibits Mechanistic 21800.0 nM (IC50) ChEMBL
DIOSMETINIDIN ↓ inhibits Mechanistic 32100.0 nM (IC50) ChEMBL
PETUNIDIN ↓ inhibits Mechanistic 39200.0 nM (IC50) ChEMBL
FISETINIDIN ↓ inhibits Mechanistic 70300.0 nM (IC50) ChEMBL
LUTEOLIN ↓ inhibits Mechanistic 8200.0 nM (IC50) ChEMBL
MYRICETIN ↓ inhibits Mechanistic 24800.0 nM (IC50) ChEMBL
QUERCETIN ↓ inhibits Mechanistic 37900.0 nM (IC50) ChEMBL
ROBINETIN ↓ inhibits Mechanistic 37900.0 nM (IC50) ChEMBL
QUERCETAGETIN ↓ inhibits Mechanistic 48600.0 nM (IC50) ChEMBL
LUTEOLINIDIN ↓ inhibits Mechanistic 6000.0 nM (IC50) ChEMBL
CHEMBL3342444 ↓ inhibits Mechanistic 3300.0 nM (IC50) ChEMBL
CHEMBL3342440 ↓ inhibits Mechanistic 6400.0 nM (IC50) ChEMBL
CHEMBL3342442 ↓ inhibits Mechanistic 33000.0 nM (IC50) ChEMBL
CHEMBL3342443 ↓ inhibits Mechanistic 27000.0 nM (IC50) ChEMBL
CHEMBL3422364 ↓ inhibits Mechanistic 14000.0 nM (IC50) ChEMBL
CHEMBL3422366 ↓ inhibits Mechanistic 26000.0 nM (IC50) ChEMBL
CHEMBL3426029 ↓ inhibits Mechanistic 55.0 nM (IC50) ChEMBL
CHEMBL3426030 ↓ inhibits Mechanistic 89.0 nM (IC50) ChEMBL
CHEMBL3426031 ↓ inhibits Mechanistic 52.0 nM (IC50) ChEMBL
CHEMBL3426032 ↓ inhibits Mechanistic 6.0 nM (IC50) ChEMBL
CHEMBL3426033 ↓ inhibits Mechanistic 3.9 nM (IC50) ChEMBL
CHEMBL3426034 ↓ inhibits Mechanistic 7.3 nM (IC50) ChEMBL
CHEMBL3426035 ↓ inhibits Mechanistic 10.0 nM (IC50) ChEMBL
CHEMBL3426036 ↓ inhibits Mechanistic 54.0 nM (IC50) ChEMBL
CHEMBL3426037 ↓ inhibits Mechanistic 3.8 nM (IC50) ChEMBL
CHEMBL3426038 ↓ inhibits Mechanistic 13.0 nM (IC50) ChEMBL

Showing top 40 of 203 agents ranked by evidence tier.

CD52

UniProt Ensembl DGIdb Open Targets
Therapeutic Agent Effect Direction Evidence Tier Potency Source
ALEMTUZUMAB ↓ inhibits Mechanistic DGIdb
ALEMTUZUMAB BETA ~ modulates Mechanistic DGIdb
GATRALIMAB ? unclear Mechanistic DGIdb
THERAPEUTIC ANDROGEN ? unclear Mechanistic DGIdb

MS4A1

UniProt Ensembl DGIdb Open Targets
Therapeutic Agent Effect Direction Evidence Tier Potency Source
RITUXIMAB ~ modulates Mechanistic DGIdb
UBLITUXIMAB ~ modulates Mechanistic DGIdb
VELTUZUMAB ? unclear Mechanistic DGIdb
OFATUMUMAB ~ modulates Mechanistic DGIdb
OBINUTUZUMAB ~ modulates Mechanistic DGIdb
OCARATUZUMAB ~ modulates Mechanistic DGIdb
TOSITUMOMAB ~ modulates Mechanistic DGIdb
TISAGENLECLEUCEL ? unclear Mechanistic DGIdb
IODINE-131-TOSITUMOMAB ? unclear Mechanistic DGIdb
EPCORITAMAB ? unclear Mechanistic DGIdb
GLOFITAMAB ~ modulates Mechanistic DGIdb
TRU-015 ~ modulates Mechanistic DGIdb
ODRONEXTAMAB ? unclear Mechanistic DGIdb
OCRELIZUMAB ~ modulates Mechanistic DGIdb
ANTI-CD20 CAR T CELLS PREPARATION ? unclear Mechanistic DGIdb
DI-LEU16-IL2 ? unclear Mechanistic DGIdb
MONOCLONAL ANTIBODY 1F5 ? unclear Mechanistic DGIdb
MT-3724 ~ modulates Mechanistic DGIdb
MOSUNETUZUMAB ? unclear Mechanistic DGIdb
PLAMOTAMAB ? unclear Mechanistic DGIdb
AUTOLOGOUS ANTI-CD20 CAR TRANSDUCED CD4/CD8 ENRICHED T-CELLS MB-CART20.1 ? unclear Mechanistic DGIdb
FBT-A05 ~ modulates Mechanistic DGIdb
YTTRIUM Y 90 IBRITUMOMAB TIUXETAN ~ modulates Mechanistic DGIdb
BSAB (CD89-CD20) ? unclear Mechanistic DGIdb
LFB-R603 ~ modulates Mechanistic DGIdb
DIVOZILIMAB ? unclear Mechanistic DGIdb
IBRITUMOMAB TIUXETAN ? unclear Mechanistic DGIdb
TOSITUMOMAB 131I ~ modulates Mechanistic DGIdb

NOTCH1

UniProt Ensembl DGIdb Open Targets
Therapeutic Agent Effect Direction Evidence Tier Potency Source
CRENIGACESTAT ? unclear Mechanistic DGIdb
NIROGACESTAT ? unclear Mechanistic DGIdb
BRONTICTUZUMAB ↓ inhibits Mechanistic DGIdb
IMR-1 ↓ inhibits Mechanistic DGIdb
MK-0752 ? unclear Mechanistic DGIdb
ENOTICUMAB ? unclear Mechanistic DGIdb
HYDROCORTISONE BUTYRATE ? unclear Mechanistic DGIdb
NOTCH SIGNALING PATHWAY INHIBITOR MK0752 ? unclear Mechanistic DGIdb
RO4929097 ↓ inhibits Mechanistic DGIdb
JAGGED2 ↑ activates Mechanistic DGIdb
CHEMBL3410170 ↓ inhibits Mechanistic 2.0 nM (IC50) ChEMBL
CHEMBL3410169 ↓ inhibits Mechanistic 1.0 nM (IC50) ChEMBL
CHEMBL3410168 ↓ inhibits Mechanistic 2.0 nM (IC50) ChEMBL
CHEMBL3410167 ↓ inhibits Mechanistic 2.0 nM (IC50) ChEMBL
CHEMBL3410166 ↓ inhibits Mechanistic 9.0 nM (IC50) ChEMBL
CHEMBL3410165 ↓ inhibits Mechanistic 2060.0 nM (IC50) ChEMBL
CHEMBL3410164 ↓ inhibits Mechanistic 3.0 nM (IC50) ChEMBL
CHEMBL3410163 ↓ inhibits Mechanistic 1.0 nM (IC50) ChEMBL
CHEMBL3410162 ↓ inhibits Mechanistic 3.0 nM (IC50) ChEMBL
CHEMBL3410161 ↓ inhibits Mechanistic 4.0 nM (IC50) ChEMBL
CHEMBL3410160 ↓ inhibits Mechanistic 3.0 nM (IC50) ChEMBL
CHEMBL3410159 ↓ inhibits Mechanistic 54.0 nM (IC50) ChEMBL
CHEMBL3410158 ↓ inhibits Mechanistic 169.0 nM (IC50) ChEMBL
CHEMBL3410157 ↓ inhibits Mechanistic 32.0 nM (IC50) ChEMBL
CHEMBL3410156 ↓ inhibits Mechanistic 231.0 nM (IC50) ChEMBL
CHEMBL3410155 ↓ inhibits Mechanistic 1190.0 nM (IC50) ChEMBL
CHEMBL3410154 ↓ inhibits Mechanistic 13.0 nM (IC50) ChEMBL
CHEMBL3410153 ↓ inhibits Mechanistic 1.0 nM (IC50) ChEMBL
CHEMBL3410152 ↓ inhibits Mechanistic 3.0 nM (IC50) ChEMBL
CHEMBL3410151 ↓ inhibits Mechanistic 2.0 nM (IC50) ChEMBL
VAREGACESTAT ↓ inhibits Mechanistic 7.8 nM (IC50) ChEMBL
CHEMBL3984405 ↓ inhibits Mechanistic 4.9 nM (IC50) ChEMBL
CHEMBL3896661 ↓ inhibits Mechanistic 1.8 nM (IC50) ChEMBL
CHEMBL3893305 ↓ inhibits Mechanistic 8.5 nM (IC50) ChEMBL
CHEMBL3915833 ↓ inhibits Mechanistic 2.3 nM (IC50) ChEMBL
CHEMBL3985584 ↓ inhibits Mechanistic 7.2 nM (IC50) ChEMBL
CHEMBL3891599 ↓ inhibits Mechanistic 4.4 nM (IC50) ChEMBL
CHEMBL3977486 ↓ inhibits Mechanistic 6.0 nM (IC50) ChEMBL
CHEMBL3913200 ↓ inhibits Mechanistic 3.0 nM (IC50) ChEMBL
CHEMBL3944645 ↓ inhibits Mechanistic 2.5 nM (IC50) ChEMBL

Showing top 40 of 122 agents ranked by evidence tier.

PIK3CD

UniProt Ensembl DGIdb Open Targets
Therapeutic Agent Effect Direction Evidence Tier Potency Source
PF-04691502 ↓ inhibits Mechanistic DGIdb
COMPOUND 27 [PMID: 35834807] ↓ inhibits Mechanistic DGIdb
AMDIZALISIB ↓ inhibits Mechanistic DGIdb
SAMOTOLISIB ↓ inhibits Mechanistic DGIdb
GEDATOLISIB ↓ inhibits Mechanistic 6.0 nM (IC50) DGIdb
FIMEPINOSTAT ↓ inhibits Mechanistic DGIdb
PICTILISIB ↓ inhibits Mechanistic 3.0 nM (IC50) DGIdb
DEZAPELISIB ↓ inhibits Mechanistic DGIdb
BGT-226 ↓ inhibits Mechanistic DGIdb
OMIPALISIB ↓ inhibits Mechanistic DGIdb
DACTOLISIB ↓ inhibits Mechanistic DGIdb
DUVELISIB ↓ inhibits Mechanistic DGIdb
LENIOLISIB ↓ inhibits Mechanistic DGIdb
RECILISIB ↓ inhibits Mechanistic DGIdb
STK16-IN-1 ↓ inhibits Mechanistic DGIdb
LENIOLISIB PHOSPHATE ↓ inhibits Mechanistic DGIdb
AMG-319 ↓ inhibits Mechanistic DGIdb
TGX-221 ↓ inhibits Mechanistic DGIdb
SF1126 ↓ inhibits Mechanistic DGIdb
PANULISIB ↓ inhibits Mechanistic DGIdb
GSK2636771 ↓ inhibits Mechanistic DGIdb
IDELALISIB ↓ inhibits Mechanistic DGIdb
NVP-CLR457 ↓ inhibits Mechanistic DGIdb
VOXTALISIB ↓ inhibits Mechanistic DGIdb
UMBRALISIB TOSYLATE ↓ inhibits Mechanistic DGIdb
WORTMANNIN ↓ inhibits Mechanistic 9.0 nM (IC50) DGIdb
IZORLISIB ↓ inhibits Mechanistic DGIdb
PWT-33587 ↓ inhibits Mechanistic DGIdb
CH-5132799 ? unclear Mechanistic DGIdb
AZD8186 ↓ inhibits Mechanistic DGIdb
PAXALISIB ↓ inhibits Mechanistic DGIdb
APITOLISIB ↓ inhibits Mechanistic DGIdb
COMPOUND 15A [PMID: 32069401] ↓ inhibits Mechanistic DGIdb
5-QUINOXALIN-6-YLMETHYLENE-THIAZOLIDINE-2,4-DIONE ↓ inhibits Mechanistic DGIdb
BUPARLISIB ↓ inhibits Mechanistic DGIdb
NEMIRALISIB ↓ inhibits Mechanistic DGIdb
PUQUITINIB MESYLATE DIHYDRATE ↓ inhibits Mechanistic DGIdb
AMG319 ↓ inhibits Mechanistic DGIdb
TASELISIB ↓ inhibits Mechanistic DGIdb
PARSACLISIB ↓ inhibits Mechanistic DGIdb

Showing top 40 of 302 agents ranked by evidence tier.

TP53

UniProt Ensembl DGIdb Open Targets
Therapeutic Agent Effect Direction Evidence Tier Potency Source
PIRARUBICIN ? unclear Mechanistic DGIdb
OXALIPLATIN ? unclear Mechanistic DGIdb
SIREMADLIN ↓ inhibits Mechanistic DGIdb
CARBOPLATIN ? unclear Mechanistic DGIdb
DAUNORUBICIN HYDROCHLORIDE ? unclear Mechanistic DGIdb
CHEMBL:CHEMBL260560 ? unclear Mechanistic DGIdb
MELPHALAN ? unclear Mechanistic DGIdb
LAPACHONE ? unclear Mechanistic DGIdb
VITAMIN K3 ? unclear Mechanistic DGIdb
CHEMBL:CHEMBL260451 ? unclear Mechanistic DGIdb
DINOSEB ? unclear Mechanistic DGIdb
RIMCAZOLE ? unclear Mechanistic DGIdb
TRACAZOLATE ? unclear Mechanistic DGIdb
CAPIVASERTIB ? unclear Mechanistic DGIdb
AZD7648 ? unclear Mechanistic DGIdb
QUINALIZARIN ? unclear Mechanistic DGIdb
INOSITOL ? unclear Mechanistic DGIdb
ECONAZOLE NITRATE ? unclear Mechanistic DGIdb
L-733,060 ? unclear Mechanistic DGIdb
U50488 ? unclear Mechanistic DGIdb
CHEMBL:CHEMBL260028 ? unclear Mechanistic DGIdb
CHEMBL:CHEMBL601140 ? unclear Mechanistic DGIdb
CHEMBL:CHEMBL408563 ? unclear Mechanistic DGIdb
ENALAPRIL MALEATE ? unclear Mechanistic DGIdb
HOMIDIUM BROMIDE ? unclear Mechanistic DGIdb
IOXYNIL ? unclear Mechanistic DGIdb
ACALABRUTINIB ? unclear Mechanistic DGIdb
INDOPROFEN ? unclear Mechanistic DGIdb
MERCAPTOPURINE ? unclear Mechanistic DGIdb
AUTOLOGOUS DENDRITIC CELLS TRANSDUCED WITH WILD-TYPE P53 ADENOVIRUS VACCINE ? unclear Mechanistic DGIdb
ZIRAM ? unclear Mechanistic DGIdb
IFOSFAMIDE ? unclear Mechanistic DGIdb
DOCETAXEL ANHYDROUS ? unclear Mechanistic DGIdb
SOTULETINIB ? unclear Mechanistic DGIdb
SERTRALINE HYDROCHLORIDE ? unclear Mechanistic DGIdb
PD166285 ? unclear Mechanistic DGIdb
SAPANISERTIB ? unclear Mechanistic DGIdb
ENZALUTAMIDE ? unclear Mechanistic DGIdb
PYRITHIONE ZINC ? unclear Mechanistic DGIdb
CHEMBL:CHEMBL1169388 ? unclear Mechanistic DGIdb

Showing top 40 of 652 agents ranked by evidence tier.

ZAP70

UniProt Ensembl DGIdb Open Targets
Therapeutic Agent Effect Direction Evidence Tier Potency Source
SYK INHIBITOR II ↓ inhibits Mechanistic DGIdb
TRIDOLGOSIR ? unclear Mechanistic DGIdb
MIVAVOTINIB ↓ inhibits Mechanistic DGIdb
HYDROGEN PEROXIDE ? unclear Mechanistic DGIdb
ALOISINE ↓ inhibits Mechanistic DGIdb
CHEMBL443592 ↓ inhibits Mechanistic 250.0 nM (IC50) ChEMBL
CHEMBL386787 ↓ inhibits Mechanistic 320.0 nM (IC50) ChEMBL
CHEMBL439120 ↓ inhibits Mechanistic 30.0 nM (IC50) ChEMBL
CHEMBL99125 ↓ inhibits Mechanistic 1900.0 nM (IC50) ChEMBL
CHEMBL319210 ↓ inhibits Mechanistic 3200.0 nM (IC50) ChEMBL
CHEMBL113185 ↓ inhibits Mechanistic 125.0 nM (IC50) ChEMBL
CHEMBL419757 ↓ inhibits Mechanistic 188.0 nM (IC50) ChEMBL
CHEMBL420672 ↓ inhibits Mechanistic 46.0 nM (IC50) ChEMBL
CHEMBL112172 ↓ inhibits Mechanistic 31.0 nM (IC50) ChEMBL
CHEMBL112346 ↓ inhibits Mechanistic 8.0 nM (IC50) ChEMBL
CHEMBL322066 ↓ inhibits Mechanistic 54.0 nM (IC50) ChEMBL
CHEMBL112518 ↓ inhibits Mechanistic 26.0 nM (IC50) ChEMBL
CHEMBL324576 ↓ inhibits Mechanistic 424.0 nM (IC50) ChEMBL
CHEMBL325912 ↓ inhibits Mechanistic 11.0 nM (IC50) ChEMBL
CHEMBL112561 ↓ inhibits Mechanistic 332.0 nM (IC50) ChEMBL
CHEMBL112263 ↓ inhibits Mechanistic 1900.0 nM (IC50) ChEMBL
CHEMBL323755 ↓ inhibits Mechanistic 396.0 nM (IC50) ChEMBL
CHEMBL112623 ↓ inhibits Mechanistic 4300.0 nM (IC50) ChEMBL
CHEMBL102765 ↓ inhibits Mechanistic 18000.0 nM (IC50) ChEMBL
CHEMBL3706656 ↓ inhibits Mechanistic 30000.0 nM (IC50) ChEMBL
CHEMBL319179 ↓ inhibits Mechanistic 40000.0 nM (IC50) ChEMBL
CHEMBL318300 ↓ inhibits Mechanistic 7000.0 nM (IC50) ChEMBL
CHEMBL102766 ↓ inhibits Mechanistic 7000.0 nM (IC50) ChEMBL
CHEMBL103838 ↓ inhibits Mechanistic 6000.0 nM (IC50) ChEMBL
CHEMBL419539 ↓ inhibits Mechanistic 22000.0 nM (IC50) ChEMBL
CHEMBL320372 ↓ inhibits Mechanistic 19000.0 nM (IC50) ChEMBL
CHEMBL316967 ↓ inhibits Mechanistic 4000.0 nM (IC50) ChEMBL
CHEMBL423330 ↓ inhibits Mechanistic 94000.0 nM (IC50) ChEMBL
CHEMBL132006 ↓ inhibits Mechanistic 4000.0 nM (IC50) ChEMBL
CHEMBL411163 ↓ inhibits Mechanistic 38.0 nM (IC50) ChEMBL
CHEMBL130106 ↓ inhibits Mechanistic 96000.0 nM (IC50) ChEMBL
CHEMBL133511 ↓ inhibits Mechanistic 72000.0 nM (IC50) ChEMBL
CHEMBL129842 ↓ inhibits Mechanistic 61000.0 nM (IC50) ChEMBL
CHEMBL134030 ↓ inhibits Mechanistic 31000.0 nM (IC50) ChEMBL
CHEMBL130931 ↓ inhibits Mechanistic 3000.0 nM (IC50) ChEMBL

Showing top 40 of 192 agents ranked by evidence tier.

Clinical Trials

Drug, biologic and supplement trials (treatment or prevention) from ClinicalTrials.gov whose main condition is Chronic Lymphocytic Leukaemia (CLL): recruiting, active or completed, most recently updated first. Data retrieved 2026-10-28.

A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies Recruiting
NCT06564038 Phase: 1/2 Started: 2025-01-30

The purpose of this study is to assess the safety and efficacy of surovatamig (formerly AZD0486) administered as monotherapy or in combination with other anticancer agents in participants with hematological malignancies

Duvelisib and Venetoclax in Relapsed or Refractory CLL or SLL or RS Completed
NCT03534323 Phase: 1/2 Started: 2018-07-12

This research study is assessing a new drug, duvelisib, in combination with a drug that is already FDA approved, venetoclax, as a possible treatment for participants with CLL or those with Richter's Syndrome

Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study Recruiting
NCT04269902 Phase: 3 Started: 2021-03-02

This phase III trial compares early treatment with venetoclax and obinutuzumab versus delayed treatment with venetoclax and obinutuzumab in patients with newly diagnosed high-risk chronic lymphocytic leukemia or small lymphocytic lymphoma. Venetoclax is in a class of medications called B-cell lympho...

A Study to Investigate the Safety of Novel Dose Ramp-up Schedule(s) When Initiating Sonrotoclax in Participants Treated for Blood Cancers. Recruiting
NCT06697184 Phase: 1/2 Started: 2025-01-23

The purpose of this study is to establish the safety of novel dosing and ramp-up schedules for sonrotoclax in participants with hematological malignancies.

Testing the Addition of a New Anti-cancer Drug, Venetoclax, to the Usual Treatment (Ibrutinib and Obinutuzumab) in Untreated, Older Patients With Chronic Lymphocytic Leukemia Active Not Recruiting
NCT03737981 Phase: 3 Started: 2019-01-31

This phase III trial compares adding a new anti-cancer drug (venetoclax) to the usual treatment (ibrutinib plus obinutuzumab) in older patients with chronic lymphocytic leukemia who have not received previous treatment. The addition of venetoclax to the usual treatment might prevent chronic lymphocy...

Acalabrutinib With or Without Obinutuzumab in Treating Patients With Early-Stage Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Recruiting
NCT03516617 Phase: 2 Started: 2018-09-10

This phase II trials studies how well acalabrutinib with or without obinutuzumab works in treating patients with early-stage chronic lymphocytic leukemia or small lymphocytic lymphoma. Acalabrutinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Immunothe...

Assessing the Ability of Combination Treatment With Venetoclax to Permit Time Limited Therapy in Chronic Lymphocytic Leukemia Active Not Recruiting
NCT03701282 Phase: 3 Started: 2019-02-12

This phase III trial studies how well ibrutinib and obinutuzumab with or without venetoclax work in treating patients with chronic lymphocytic leukemia. Ibrutinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Obinutuzumab is a monoclonal antibody. It bin...

A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL) Recruiting
NCT06943872 Phase: 3 Started: 2025-06-11

The goal of this study is to compare how well sonrotoclax plus obinutuzumab works versus venetoclax plus rituximab in treating adults with relapsed and/or refractory (R/R) chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). The study will also compare how well sonrotoclax plus rituxim...

MAVRiC Studies 2L Treatment With AV in Patients With CLL/SLL Who Have Relapsed After a Course of BTKi + BCL2i Combination, With or Without Obinutuzumab Recruiting
NCT07024706 Phase: 2 Started: 2026-06-04

This study will evaluate the efficacy and safety of finite-duration acalabrutinib plus venetoclax therapy in patients with relapsed CLL or SLL, who have previously responded to first line (1L) cBTKi + BCL2i therapy (± obinutuzumab) and maintained a response for at least two years post-treatment.

Acalabrutinib in Combination With Venetoclax for the Treatment of Refractory or Recurrent Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma, The AVENUE-2 Trial Recruiting
NCT04941716 Phase: 2 Started: 2023-05-31

This phase II trial is to evaluate the effects of acalabrutinib in combination with venetoclax in treating patients with chronic lymphocytic leukemia or small lymphocytic lymphoma that does not respond to treatment (refractory) or that has come back (recurrent). Acalabrutinib may stop the growth of ...

A Study of Acalabrutinib vs Investigator's Choice of Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in R/R CLL Active Not Recruiting
NCT02970318 Phase: 3 Started: 2017-02-02

This study is designed to evaluate the efficacy of acalabrutinib compared with rituximab in combination with idelalisib or bendamustine in previously treated subjects with chronic lymphocytic leukemia (CLL).

Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax in Combination With Intravenous (IV) Obinutuzumab or Oral Ibrutinib in Adult Participants With Untreated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) Completed
NCT05105841 Phase: 2 Started: 2021-11-08

Chronic lymphocytic leukemia (CLL) is the most common leukemia in Western countries, representing approximately 30% of all adult leukemias. There is a large difference in proportion of malignant lymphoma between the United States (US) and Japan was seen in CLL/small lymphocytic lymphoma (SLL) (Japan...

Phase 2 Study of Glofitamab Monotherapy & With Polatuzumab Vedotin, Pirtobrutinib, or Atezolizumab in Richter's Transformation Recruiting
NCT06043674 Phase: 2 Started: 2024-01-22

This research is being done to evaluate Glofitamab by itself or in combination with Polatuzumab Vedotin, Pirtobrutinib, or Atezolizumab as possible treatments for Chronic Lymphocytic Leukemia (CLL) that has transformed into Richter's Transformation (RT). The names of the study drugs involved in this...

Addition of Loncastuximab Tesirine to Acalbrutinib , Chronic Lymphocytic Leukemia Active Not Recruiting
NCT05971251 Phase: 1 Started: 2023-12-18

Study is a phase I study to determine the maximum tolerated dose of adding Loncastuximab Tesirine to Aclabrutinib in the treatment of chronic lymphocytic leukemia.

Trial of Anti-CD19 and Anti-CD20 Bicistronic Chimeric Antigen Receptor T Cells for Treating B-Cell Malignancies Active Not Recruiting
NCT05797233 Phase: 1 Started: 2023-08-28

Background: About 23,000 people die from B-cell cancers in the US each year. These cancers, often called leukemia or lymphoma, affect a type of white blood cell called B cells. These cancers are difficult to treat, and the therapies used can have bad side effects. Researchers want to try a new type ...

Agents Found By Disease-Level Search

Searched directly from “Chronic Lymphocytic Leukaemia (CLL)” via ClinicalTrials.gov interventions and Open Targets' disease→drug data — independent of the 11-gene target panel above. This surfaces agents whose mechanism doesn't route through a curated gene (combination therapies, standard-of-care drugs, targets outside the panel).

47 agents shown (approved or with trial evidence) — 29 not found by the gene-target search above.

rituximab

Approved · 16 trials · source: ClinicalTrials.gov, Open Targets
NCT01998880 NCT00004112 NCT00669318

cyclophosphamideNOT in gene-target list

Phase 3 · 12 trials · source: ClinicalTrials.gov, Open Targets
NCT00621452 NCT00003116 NCT00005854

cyclosporineNOT in gene-target list

Phase 2 · 9 trials · source: ClinicalTrials.gov, Open Targets
NCT00003116 NCT00005854 NCT00112593

fludarabine phosphateNOT in gene-target list

Approved · 8 trials · source: ClinicalTrials.gov, Open Targets
NCT01658319 NCT00856388 NCT00112593

Ibrutinib

Approved · 7 trials · source: ClinicalTrials.gov, Open Targets
NCT02759016 NCT02048813 NCT02264574

Fludarabine

Phase 3 · 6 trials · source: ClinicalTrials.gov, Open Targets
NCT00276848 NCT05797233 NCT02251548

Mycophenolate mofetilNOT in gene-target list

Phase 2 · 6 trials · source: ClinicalTrials.gov, Open Targets
NCT04473911 NCT00112593 NCT02593123

Melphalan

Phase 2 · 5 trials · source: ClinicalTrials.gov, Open Targets
NCT04473911 NCT00244946 NCT00856388

filgrastimNOT in gene-target list

Phase 3 · 4 trials · source: ClinicalTrials.gov, Open Targets
NCT00003116 NCT03147612 NCT00002832

cytarabine

Phase 2 · 4 trials · source: ClinicalTrials.gov, Open Targets
NCT00244946 NCT00080886 NCT03147612

methotrexate

Phase 2 · 4 trials · source: ClinicalTrials.gov, Open Targets
NCT00005854 NCT00521430 NCT00317785

busulfanNOT in gene-target list

Phase 2 · 3 trials · source: ClinicalTrials.gov, Open Targets
NCT00003116 NCT00003335 NCT00521430

Sirolimus

Phase 3 · 3 trials · source: ClinicalTrials.gov, Open Targets
NCT04473911 NCT01251575 NCT00317785

obinutuzumab

Approved · 3 trials · source: ClinicalTrials.gov, Open Targets
NCT01998880 NCT02264574 NCT04434196

Ofatumumab

Approved · 3 trials · source: ClinicalTrials.gov, Open Targets
NCT01244451 NCT02135133 NCT01455051

Bendamustine

Phase 3 · 3 trials · source: ClinicalTrials.gov, Open Targets
NCT01244451 NCT02970318 NCT01400685

anti-thymocyte globulinNOT in gene-target list

· 3 trials · source: ClinicalTrials.gov
NCT00856388 NCT00003335 NCT00521430

Lenalidomide

Phase 3 · 3 trials · source: ClinicalTrials.gov, Open Targets
NCT00774345 NCT01400685 NCT00096044

Idelalisib

Approved · 3 trials · source: ClinicalTrials.gov, Open Targets
NCT02970318 NCT02135133 NCT02787369

BI 836826NOT in gene-target list

Phase 1 · 2 trials · source: ClinicalTrials.gov, Open Targets
NCT02759016 NCT01296932

therapeutic autologous lymphocytesNOT in gene-target list

· 2 trials · source: ClinicalTrials.gov
NCT00621452 NCT00244946

polymerase chain reactionNOT in gene-target list

· 2 trials · source: ClinicalTrials.gov
NCT00621452 NCT01005368

bone marrow aspirationNOT in gene-target list

· 2 trials · source: ClinicalTrials.gov
NCT00621452 NCT06757647

western blottingNOT in gene-target list

· 2 trials · source: ClinicalTrials.gov
NCT01658319 NCT01005368

Venetoclax

Approved · 2 trials · source: ClinicalTrials.gov, Open Targets
NCT02980731 NCT02966756

Zilovertamab vedotinNOT in gene-target list

· 2 trials · source: ClinicalTrials.gov
NCT03833180 NCT05458297

carmustineNOT in gene-target list

Phase 2 · 2 trials · source: ClinicalTrials.gov, Open Targets
NCT00244946 NCT00080886

etoposide

Phase 2 · 2 trials · source: ClinicalTrials.gov, Open Targets
NCT00244946 NCT00080886

paclitaxelNOT in gene-target list

Phase 2 · 2 trials · source: ClinicalTrials.gov, Open Targets
NCT00004105 NCT00891072

chlorambucil

Phase 3 · 2 trials · source: ClinicalTrials.gov, Open Targets
NCT01998880 NCT02264574

PegfilgrastimNOT in gene-target list

Phase 2 · 2 trials · source: ClinicalTrials.gov, Open Targets
NCT03147612 NCT00472849

doxorubicin hydrochloride

Phase 3 · 2 trials · source: ClinicalTrials.gov, Open Targets
NCT00004112 NCT00036790

Computed TomographyNOT in gene-target list

· 2 trials · source: ClinicalTrials.gov
NCT06757647 NCT06839053

SargramostimNOT in gene-target list

Phase 2 · 2 trials · source: ClinicalTrials.gov, Open Targets
NCT02593123 NCT00669318

alemtuzumab

Approved · 2 trials · source: ClinicalTrials.gov, Open Targets
NCT00669318 NCT01392079

methylprednisolone

Phase 3 · 2 trials · source: ClinicalTrials.gov, Open Targets
NCT00003335 NCT00521430

aldesleukinNOT in gene-target list

Phase 2 · 1 trial · source: ClinicalTrials.gov, Open Targets
NCT00621452

gene rearrangement analysisNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT00621452

genetically engineered lymphocyte therapyNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT00621452

ixabepiloneNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT00006221

Routine Blood Draw - Phase 1 onlyNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT06224309

Fludarabine plus CyclophosphamideNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT00276848

becatecarinNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT00087204

methoxyamineNOT in gene-target list

Phase 1 · 1 trial · source: ClinicalTrials.gov, Open Targets
NCT01658319

DNA analysisNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT01658319

TBINOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT04473911

RGI-2001NOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT04473911

Generated by the Open Source Medicine Foundation Biomarker Pipeline — 2026-10-08. Data sources: DGIdb, Open Targets, ChEMBL, PubMed, ClinicalTrials.gov. Not medical advice.